Study Title
An Open-label Dosimetry, Biodistribution, Tolerability and Safety Study of Lutetium (177Lu) Vipivotide Tetraxetan in Participants With Progressive PSMA-Positive Metastatic Castration-Resistant Prostate Cancer (mCRPC) With Moderately and Severely Impaired and With Normal Renal Function.
Study Details
Description:
This open-label, non-randomized, multicenter, single arm phase II study in mCRPC participants aims to better characterize the safety and tolerability of AAA617 in participants with moderate and severe renal impairment compared with normal renal function.
Sponsor:
NovartisContacts:
Novartis Pharmaceuticalsnovartis.email@novartis.com
1-888-669-6682 or +41613241111
Government Study Link:
NCT06004661 - Click here to see study onClinicalTrials.gov
Patient Education
Patient Education Not Yet Provided
Publications
Publications Not Yet Provided
Locations
Not yet provided. Contact Novartis Pharmaceuticals for more information.
1-888-669-6682 or +41613241111
novartis.email@novartis.com